Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma

Clinical Cancer Research

Volumn 21, Issue 15, 2015, Pages 3512-3521

  Radon, Tomasz P ^a   Massat, Nathalie J ^a   Jones, Richard ^b   Alrawashdeh, Wasfi ^a   Dumartin, Laurent ^a   Ennis, Darren ^a   Duffy, Stephen W ^a   Kocher, Hemant M ^a   Pereira, Stephen P ^c   Guarner, Luisa ^d   Murta Nascimento, Cristiane ^e   Real, Francisco X ^f   Malats, Núria ^f   Neoptolemos, John ^g   Costello, Eithne ^g   Greenhalf, William ^g   Lemoine, Nick R ^a   Crnogorac Jurcevic, Tatjana ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MS BIOWORKS   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f Structural Biology and Biocomputing Programme   (Spain)

^g Liverpool NIHR Pancreas Biomedical Research Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; LYVE 1 PROTEIN; REG1A PROTEIN; TFF1 PROTEIN; UNCLASSIFIED DRUG; CARBOHYDRATE ANTIGEN 199, HUMAN; LITHOSTATHINE; LYVE1 PROTEIN, HUMAN; PROTEOME; REG1A PROTEIN, HUMAN; TFF1 PROTEIN, HUMAN; TREFOIL FACTOR 1; TUMOR ANTIGEN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; VESICULAR TRANSPORT PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CHRONIC PANCREATITIS; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; ADENOCARCINOMA; EARLY CANCER DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; URINE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LITHOSTATHINE; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROTEOME; TANDEM MASS SPECTROMETRY; TREFOIL FACTOR-1; TUMOR SUPPRESSOR PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 84942883362     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2467     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013;24:792-800.
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21.
4. Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986;203:77-81.
5. Furukawa H, Okada S, Saisho H, Ariyama J, Karasawa E, Nakaizumi A, et al. Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 1996;78:986-90.
6. Shimizu Y, Yasui K, Matsueda K, Yanagisawa A, Yamao K. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005;20:1591-4.
7. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 2012;6:597-612.
8. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002;51:849-52.
9. Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a biomarker for pancreatic cancer-A comprehensive review. Indian J Surg Oncol 2011;2:88-100.
10. Weeks ME, Hariharan D, Petronijevic L, Radon TP, Whiteman HJ, Kocher HM, et al. Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. Proteom Clin Appl 2008;2:1047-57.
11. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-201.
12. Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, et al. Activated pancreatic stellate cells sequester CD8+T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 2013;145:1121-32.
13. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
14. Rota M, Antolini L. Finding the optimal cut-point for Gaussian and Gamma distributed biomarkers. Comput Stat Data An 2014;69:1-14.
15. De Long ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
16. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19:1141-64.
17. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005;21:3940-1.
18. Dayem Ullah AZ, Cutts RJ, Ghetia M, Gadaleta E, Hahn SA, Crnogorac-Jurcevic T, et al. The pancreatic expression database: recent extensions and updates. Nucl Acids Res 2014;42:D944-9.
19. Kentsis A, Monigatti F, Dorff K, Campagne F, Bachur R, Steen H. Urine proteomics for profiling of human disease using high accuracy mass spectrometry. Proteom Clin Appl 2009;3:1052-61.
20. Jia L, Zhang L, Shao C, Song E, Sun W, Li M, et al. An attempt to understand kidney's protein handling function by comparing plasma and urine proteomes. PloS One 2009;4:e5146.
21. Liu X, Shao C, Wei L, Duan J, Wu S, Li X, et al. Anindividual urinary proteome analysis in normal human beings to define the minimal sample number to represent the normal urinary proteome. Proteome Sci 2012;10:70.
22. Wu H, Zheng Q, Rengabhashyam P, Zenilman ME. A brief history of pancreatic reg: implications as to its clinical importance. Einstein Q J Biol Med 2000;17:178.
23. Zhang YW, Ding LS, Lai MD. Reg gene family and human diseases. World J Gastroenterol 2003;9:2635-41.
24. Watanabe T, Yonemura Y, Yonekura H, Suzuki Y, Miyashita H, Sugiyama K, et al. Pancreatic beta-cell replication and amelioration of surgical diabetes by Reg protein. Proc Natl Acad Sci U S A 1994;91:3589-92.
25. Parikh A, Stephan AF, Tzanakakis ES. Regenerating proteins and their expression, regulation and signaling. Biomol Concepts 2012;3:57-70.
26. Sanchez D, Mueller CM, Zenilman ME. Pancreatic regenerating gene I and acinar cell differentiation: influence on cellular lineage. Pancreas 2009;38:572-7.
27. Zenilman ME, Perfetti R, Swinson K, Magnuson T, Shuldiner AR. Pancreatic regeneration (reg) gene expression in a rat model of islet hyperplasia. Surgery 1996;119:576-84.
28. Kimura N, Yonekura H, Okamoto H, Nagura H. Expression of human regenerating gene mRNA and its product in normal and neoplastic human pancreas. Cancer 1992;70:1857-63.
29. Sanchez D, Figarella C, Marchand-Pinatel S, Bruneau N, Guy-Crotte O. Preferential expression of reg I beta gene in human adult pancreas. Biochem Biophys Res Commun 2001;284:729-37.
30. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008;5:e123.
31. Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, et al. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer 2013;13:404.
32. Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, et al. Trefoil factor family (TFF) peptides and cancer progression. Peptides 2004;25:885-98.
33. Perry JK, Kannan N, Grandison PM, Mitchell MD, Lobie PE. Are trefoil factors oncogenic? Trends Endocrinol Metab 2008;19:74-81.
34. Arumugam T, Brandt W, Ramachandran V, Moore TT, Wang H, May FE, et al. Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Pancreas 2011;40:815-22.
35. Prasad NB, Biankin AV, Fukushima N, Maitra A, Dhara S, Elkahloun AG, et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 2005;65:1619-26.
36. Crnogorac-Jurcevic T, Chelala C, Barry S, Harada T, Bhakta V, Lattimore S, et al. Molecular analysis of precursor lesions in familial pancreatic cancer. PloS One 2013;8:e54830.
37. Sagol O, Tuna B, Coker A, Karademir S, Obuz F, Astarcioglu H, et al. Immunohistochemical detection of pS2 protein and heat shock protein-70 in pancreatic adenocarcinomas. Relationship with disease extent and patient survival. Pathol Res Pract 2002;198:77-84.
38. Rinnert M, Hinz M, Buhtz P, Reiher F, Lessel W, Hoffmann W. Synthesis and localization of trefoil factor family (TFF) peptides in the human urinary tract and TFF2 excretion into the urine. Cell Tissue Res 2010;339:639-47.
39. Jackson DG. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol Rev 2009;230:216-31.
40. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001;22:317-21.
41. Sipos B, Kojima M, Tiemann K, Klapper W, Kruse ML, Kalthoff H, et al. Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J Pathol 2005;207:301-12.
42. Schneider M, Buchler P, Giese N, Giese T, Wilting J, Buchler MW, et al. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol 2006;28:883-90.
43. Mouta Carreira C, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001;61:8079-84.
44. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 2014;21:622-31.
45. Templeton AW, Brentnall TA. Screening and surgical outcomes of familial pancreatic cancer. Surg Clin North Am 2013;93:629-45.
46. Wada K, Takaori K, Traverso LW, Hruban RH, Furukawa T, Brentnall TA, et al. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. J Hepatobiliary Pancreat Sci 2013;20:557-66.
47. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339-47.
48. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
49. Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 2015;0:1-7.
50. Hippisley-Cox J, Coupland C. Identifying patients with suspected pancreatic cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012;62:e38-45.
51. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open 2014;4:e005720.